Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04996719 · ClinicalTrials.gov registry record · Phase 1
Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults
A Phase 1 study of Heart Failure, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04996719: Completed Phase 1 study of Heart Failure, sponsored by Mayo Clinic.
NCT04996719 is a Phase 1 study of Heart Failure that has completed, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04996719, a Phase 1 study of Heart Failure, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to see if the drug rapamycin will improve the heart's ability to pump by improving your oxygen consumption.
Conditions Studied
Interventions
- DRUG Rapamune
Study Locations (1)
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-05-24 |
| Est. Completion | 2023-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04996719
The ClinicalTrials.gov registry entry for NCT04996719 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Rapamune is the first listed.
NCT04996719 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04996719 about?
NCT04996719 is a clinical study titled "Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults". The purpose of this research is to see if the drug rapamycin will improve the heart's ability to pump by improving your oxygen consumption.
What is the current status of trial NCT04996719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-05-24. Estimated completion is 2023-08-25.
What conditions does trial NCT04996719 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT04996719?
The interventions under investigation include: Rapamune (DRUG).
Who is sponsoring clinical trial NCT04996719?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04996719 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
-
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
RECRUITING · Phase 1
-
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
RECRUITING · Phase 1
-
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.